Neuromuscular Blockade During Transurethral Resection of Bladder Cancer

• Status: Completed
• Trial end date: 2017-11-10
• Target enrollment: 0
• Participant gender: All

Summary

Transurethral resection of the bladder tumor (TURB) for bladder tumor excision is the mainstream treatment. However, the beneficial effects of sugammadex after general anesthesia for TURB have not been thoroughly evaluated. Investigators hypothesized that deep NMB and the use of sugammadex as a reversal agent may be associated with better endoscopic surgical condition and recovery profile compared with moderate NMB during TURB.

This study was designed to compare patients with deep neuromuscular blockade (NMB) with moderate NMB during transurethral resection of the bladder tumor (TURB) in terms of surgical condition and postoperative recovery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Bundang Hospital
• Collaborator: MSD Korea Ltd.
• Treatments: Rocuronium

Criteria

Inclusion Criteria:

• Patients aged more than 18 years

• American Society of Anesthesiologists (ASA) physical status I and II

• scheduled to undergo elective Transurethral resection of the bladder tumor (TURB)

Exclusion Criteria:

• history of neuromuscular, renal, or hepatic disease

• a body mass index (BMI) of < 18.5 or > C 30.0 kg/m2

• treatment with drugs known to interfere with neuromuscular function